Phibro Animal Health Corporation $PAHC Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. trimmed its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 19.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 196,830 shares of the company’s stock after selling 47,412 shares during the period. Goldman Sachs Group Inc. owned approximately 0.49% of Phibro Animal Health worth $4,204,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Nuveen LLC acquired a new stake in shares of Phibro Animal Health during the first quarter valued at about $10,312,000. Invesco Ltd. grew its stake in shares of Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after acquiring an additional 186,087 shares in the last quarter. Axecap Investments LLC acquired a new stake in shares of Phibro Animal Health during the first quarter valued at about $3,696,000. Millennium Management LLC grew its stake in shares of Phibro Animal Health by 74.3% during the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after acquiring an additional 154,281 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Phibro Animal Health by 711.1% during the first quarter. Russell Investments Group Ltd. now owns 122,600 shares of the company’s stock valued at $2,619,000 after acquiring an additional 107,485 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PAHC has been the topic of several research analyst reports. Morgan Stanley set a $34.00 price target on shares of Phibro Animal Health in a research report on Thursday, August 28th. BNP Paribas upgraded shares of Phibro Animal Health to a “hold” rating in a research note on Monday, June 16th. JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their price target for the company from $25.00 to $35.00 in a research note on Monday, July 7th. BNP Paribas Exane upgraded shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research note on Monday, June 16th. Finally, Bank of America lifted their price target on shares of Phibro Animal Health from $19.00 to $27.00 and gave the stock an “underperform” rating in a research report on Friday, August 29th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $28.40.

Insider Activity

In other news, CEO Jack Bendheim sold 3,520 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $41.29, for a total transaction of $145,340.80. Following the completion of the sale, the chief executive officer owned 41,880 shares of the company’s stock, valued at $1,729,225.20. This represents a 7.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 50.07% of the stock is owned by corporate insiders.

Phibro Animal Health Stock Down 1.1%

Shares of PAHC opened at $38.58 on Thursday. The company has a 50-day simple moving average of $32.50 and a 200-day simple moving average of $25.85. The firm has a market capitalization of $1.56 billion, a P/E ratio of 32.70, a P/E/G ratio of 1.16 and a beta of 0.89. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. Phibro Animal Health Corporation has a 52 week low of $16.16 and a 52 week high of $41.57.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.05. The business had revenue of $378.70 million for the quarter, compared to analysts’ expectations of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, equities research analysts expect that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd will be issued a $0.12 dividend. The ex-dividend date is Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.2%. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.